196. Anticancer Agents Med Chem. 2018 May 10. doi: 10.2174/1871520618666180510121431. [Epub ahead of print]Selection of G1-PABA as a GPER1 ligand compared to phenol red via a ligand-based virtual screening coupled to molecular dynamics simulations and itsanti-proliferative effects on breast cancer cells.Jose CB(1), Trujillo-Ferrara JG(1), Irene ML(1), Alfonso DG(2), Alma CB(3),Marlet MA(1), Bello M(1), Ruben GSJ(4), Jonathan FM(5), David ML(1), BerenicePM(1), Alberto MM(1).Author information: (1)Laboratorio de Modelado Molecular y Diseno de farmacos, Laboratorio deBioquimica, Seccion de Estudios de Posgrado e Investigacion, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Miron, 11340Ciudad de Mexico. Mexico.(2)Unidad de Investigacion Biomedica en Cancer, Instituto de InvestigacionesBiomédicas UNAM/Instituto Nacional de Cancerologia, Ciudad de Mexico. Mexico.(3)Instituto Nacional de Cancerologia, Ciudad de Mexico, Tlalpan 14080. Mexico.(4)Laboratorio de Oncologia Molecular y estres oxidativo, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto PolitecnicoNacional, Plan de San Luis y Diaz Miron, 11340 Ciudad de Mexico. Mexico.(5)Departamento de Quimica Organica, Escuela Nacional de Ciencias, Biologicas,Instituto Politecnico Nacional, Prolongacion de Carpio y Plan de Ayala, 11340,Ciudad de Mexico. Mexico.Recent reports have demonstrated the role of the G protein-coupled estrogenreceptor (GPER1) on the growth and proliferation of breast cancer cells. Thecoupling of GPER1 to estrogen, tamoxifen or fulvestrant triggers cellularsignaling pathways (PI3K and ERK) related to cell proliferation. In an effort to develop new therapeutic strategies against breast cancer, we performed an insilico study to explore the binding pose of a set of designed G15 and G1 analoguecompounds, including phenol red. First, we included a carboxyl group instead ofthe acetyl group from G1 to form amides with several moieties to increase theaffinity for GPER1. Then, all the target compounds were submitted to an in silicoADMET study. Then, the ligands were coupled to GPER1 using ligand-based virtualscreening to finally achieve molecular dynamics simulations of the best molecule on GPER1, as well as of phenol red, to explore its recognition properties.According to the in silico ADMET and docking studies, the best molecule was namedG1-PABA((3aS,4R,9bR)-4-(6-bromobenzo[d][1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-carboxylic acid). It was synthesized and assayed in vitro inbreast cancer (MCF-7 and MDA-MB-231) and normal (MCF-10A) cell lines.Experimental assays showed that the target compound was able to decrease cellproliferation, showing IC50 values of 15.93 µM, 52.92 µM and 32.45 µM in theMCF-7, MDA-MB-231 and MCF-10A cell lines, respectively, after 72 h of treatment. Interestingly, the target compound showed better IC50 values without phenol red, suggesting that phenol red could interfere with the G1-PABA action at GPER, whichis present in MCF-7 cells according to PCR studies and explains the cellproliferation effects. In conclusion, a concentration-dependent inhibition ofcell proliferation occurred with G1-PABA in the assayed cell lines and could bedue to its action on GPER1.Copyright© Bentham Science Publishers; For any queries, please email atepub@benthamscience.org.DOI: 10.2174/1871520618666180510121431 PMID: 29745344 